INTRODUCTION {#s1}
============

Drug addiction is widespread in the world. The number of drug addicts is increasing every year. Previous study have suggested that the drug addiction is a multifactorial process which is influenced by many factors, such as impulsivity, risk taking, anxiety, depression and stress responsivity as well as gene variation \[[@R1], [@R2]\]. Among these factors, environment factors and curiosity were considered as the most important reason for initial drug use; however, recent study shown that the contribution of inherited factors (mainly genetic) to development of drug addictions is approximately 50% \[[@R3]\].

Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme in the oxidation process of acetaldehyde to acetate. Genome wide association studies have demonstrated that genetic polymorphisms in *ALDH2* are associated with many alcohol-related conditions \[[@R4]--[@R6]\], which has led to studies of the association between *ALDH2* and various cancers and disease. For example, rs671 in *ALDH2* was found to be associated with accelerated deterioration of bone marrow in Japanese anemia patients \[[@R7]\]. Rs886205 in *ALDH2* has been identified as a risk marker for esophagus cancer in African populations \[[@R8]\]. However, few studies have investigated the association between genetic polymorphisms in *ALDH2* and the risk of drug addiction.

To investigate the association between *ALDH2* and drug addiction risk, we genotyped eight variants in *ALDH2* associated with alcohol dependence and performed a comprehensive association analysis to identify SNPs associated with drug addiction risk in a Chinese Han population.

RESULTS {#s2}
=======

This study included 692 drug addicts (594 men, 98 women; mean age 44.66±6.12 years) and 700 healthy controls (393 men, 307 women; mean age 48.53±9.44 years). The clinical characteristics of cases and controls are shown in Table [1](#T1){ref-type="table"}. Age (*p*\<0.001) and sex (*p*\<0.001) were significantly different between cases and healthy controls. Multivariate analyses were adjusted for age and sex.

###### Characteristics of cases and controls in this study

  Variables      Case (N=692)   Control (N=700)   Total       *p*-value
  -------------- -------------- ----------------- ----------- ----------------------------------------------
  Sex, No.(%)                                                 \< 0.001[^a^](#tfn_001){ref-type="table-fn"}
   Male          594 (85.8)     393 (56.1)        987(70.9)   
   Female        98 (14.2)      307 (43.9)        405(29.1)   
  Mean age ±SD   44.66±6.12     48.53±9.44                    \< 0.001[^b^](#tfn_002){ref-type="table-fn"}

*P* values was calculated from Pearson\'s chi-square tests.

*P* values was calculated by Welch\'s t tests.

The minor allele frequencies (MAFs) of the analyzed SNPs in the case and control groups are shown in Table [2](#T2){ref-type="table"}. All SNPs were in Hardy-Weinberg equilibrium (HWE) in the controls (*p* \> 0.05) with the exception of rs2238152, rs4648328 and rs7296651, which were excluded from subsequent analyses. Using chi-square tests, we determined that rs671 was significantly associated with a 1.551-fold increased drug addiction risk (95% CI = 1.263-1.903; *p* \< 0.001), which remained significant after Bonferroni correction (*p*\<0.00125).

###### Allele frequencies in cases and controls and odds ratio estimates for drug addiction

  SNP ID       Gene      Band       Alleles A[^a^](#tfn_003){ref-type="table-fn"}/B   MAF     HWE *p*-value   ORs                                          95% CI   *p*-value     
  ------------ --------- ---------- ------------------------------------------------- ------- --------------- -------------------------------------------- -------- ------------- ---------------------------------------------
  rs886205     *ALDH2*   12q24.12   A/G                                               0.118   0.140           0.084                                        0.825    0.661-1.031   0.091
  rs2238152    *ALDH2*   12q24.12   T/G                                               0.278   0.282           0.024[^\#^](#tfn_004){ref-type="table-fn"}   0.980    0.830-1.157   0.813
  rs4648328    *ALDH2*   12q24.12   T/C                                               0.277   0.285           0.041[^\#^](#tfn_004){ref-type="table-fn"}   0.963    0.817-1.136   0.658
  rs441        *ALDH2*   12q24.12   C/T                                               0.277   0.284           0.052                                        0.966    0.819-1.141   0.689
  rs4646778    *ALDH2*   12q24.12   A/C                                               0.278   0.284           0.051                                        0.970    0.822-1.145   0.720
  rs671        *ALDH2*   12q24.12   A/G                                               0.190   0.131           0.619                                        1.551    1.263-1.903   \< 0.001[\*](#tfn_004){ref-type="table-fn"}
  rs11066028   *ALDH2*   12q24.12   A/C                                               0.095   0.094           0.501                                        1.013    0.785-1.036   0.922
  rs7296651    *ALDH2*   12q24.12   C/G                                               0.121   0.144           0.021[^\#^](#tfn_004){ref-type="table-fn"}   0.814    0.653-1.014   0.066

MAF, minor allelic frequency; HWE, Hardy-Weinberg Equilibrium; ORs, odds ratios; CI: confidence interval.

Minor allele;

HWE *p*-value ≤ 0.05 was excluded;

*p* value ≤ 0.05.

Bonferroni\'s multiple adjustment was applied, with *p*\<0.00125 (0.05/40).

The genotype frequencies of the *ALDH2* polymorphisms were shown in Table [3](#T3){ref-type="table"}. Compared with the "CC" genotype, the "AC" frequency of rs4646778 polymorphism among cases were significantly different from the controls (AC vs. CC: OR= 1.271, 95% CI = 1.001-1.614; *p* = 0.048), which suggested that the rs4646778 polymorphism had an increased effect on drug addiction risk. Similarly, compared with individuals with the rs671 "GG" genotype, individuals with "AA" genotype had a significantly increased drug addiction risk (AA vs. GG: OR= 2.638, 95% CI = 1.180-5.899; *p* = 0.018). In addition, individuals with rs671 "AG" genotype also had a significantly increased drug addiction risk compared with "GG" genotype (AG vs. GG: OR= 1.646, 95% CI = 1.269-2.133; *p* \< 0.001), which remained significant after Bonferroni correction (*p*\<0.00125).

###### Genotypes distribution of SNPs and their associations with the risk of drug addiction

  SNP ID       Alleles A[^a^](#tfn_006){ref-type="table-fn"}/B   genotype   No. (frequency)   Logistic regression                        
  ------------ ------------------------------------------------- ---------- ----------------- --------------------- -------------------- ---------------------------------------------
  rs886205     A/G                                               GG         537(77.6)         512(73.1)             1                    
                                                                 AA         9(1.3)            8(1.1)                0.696(0.255-1.902)   0.479
                                                                 AG         146(21.1)         180(25.8)             0.770(0.587-1.008)   0.057
  rs441        C/T                                               TT         347(50.1)         369(52.7)             1                    
                                                                 CC         39(5.7)           67(9.6)               0.655(0.414-1.036)   0.070
                                                                 CT         306(44.2)         264(37.7)             1.262(0.994-1.602)   0.056
  rs4646778    A/C                                               CC         346(50.1)         369(52.8)             1                    
                                                                 AA         39(5.6)           67(9.6)               0.657(0.415-1.040)   0.073
                                                                 AC         306(44.3)         263(37.6)             1.271(1.001-1.614)   0.048[\*](#tfn_007){ref-type="table-fn"}
  rs671        A/G                                               GG         452(65.3)         526(75.1)             1                    
                                                                 AA         23(3.3)           10(1.4)               2.638(1.180-5.899)   0.018[\*](#tfn_007){ref-type="table-fn"}
                                                                 AG         217(31.4)         164(23.5)             1.646(1.269-2.133)   \< 0.001[\*](#tfn_007){ref-type="table-fn"}
  rs11066028   A/C                                               CC         568(82.1)         573(81.9)             1                    
                                                                 AA         7(1.0)            4(0.6)                1.409(0.392-5.509)   0.569
                                                                 AC         117(16.9)         123(17.5)             0.935(0.692-1.263)   0.662

^a^ Minor alleles, OR: Odds ratio, CI: Confidence interval;

*p* value were calculated by unconditional logistic regression adjusted by gender and age;

*p* ≤ 0.05; Bonferroni\'s multiple adjustment was applied, with *p*\<0.00125.

We further assessed the association between each SNP and drug addiction risk in an unconditional logistic regression analysis, which was performed using three models: additive, dominant and recessive model (Table [4](#T4){ref-type="table"}). The minor allele A of rs886205 was associated with a decreased drug addiction risk under additive model (OR= 0.782, 95% CI = 0.613-0.998; *p* = 0.048). The minor alleles C of rs441 and A of rs4646778 also displayed significantly decreased drug addiction risk under recessive model (rs441: OR= 0.591, 95% CI = 0.378-0.924; *p* = 0.021; rs4646778: OR= 0.592, 95% CI = 0.378-0.923; *p* = 0.021). Additionally, the minor allele A of rs671 displayed a remarkable increased drug addiction risk under additive model (OR= 1.640, 95% CI = 1.307-2.057; *p* \< 0.001), dominant model (OR= 1.706, 95% CI = 1.325-2.196; *p* \< 0.001) and recessive model (OR= 2.293, 95% CI = 1.030-2.106; *p* = 0.017). However, only rs671 remained significant in the additive and dominant model after Bonferroni correction (*p*\<0.00125).

###### Association between SNPs and drug addiction in multiple inheritance models

  SNP ID       Minor allele   Additive model   Dominant model   Recessive model                                                                                                                         
  ------------ -------------- ---------------- ---------------- --------------------------------------------- ------- ------------- --------------------------------------------- ------- ------------- ------------------------------------------
  rs886205     A              0.782            0.613-0.998      0.048[\*](#tfn_008){ref-type="table-fn"}      0.765   0.587-0.997   0.047                                         0.740   0.271-2.018   0.556
  rs441        C              0.996            0.831-1.195      0.969                                         1.144   0.911-1.437   0.247                                         0.591   0.378-0.924   0.021[\*](#tfn_008){ref-type="table-fn"}
  rs4646778    A              1.000            0.834-1.200      0.996                                         1.151   0.917-1.446   0.226                                         0.592   0.378-0.923   0.021[\*](#tfn_008){ref-type="table-fn"}
  rs671        A              1.640            1.307-2.057      \< 0.001[\*](#tfn_008){ref-type="table-fn"}   1.706   1.325-2.196   \< 0.001[\*](#tfn_008){ref-type="table-fn"}   2.293   1.030-2.106   0.042[\*](#tfn_008){ref-type="table-fn"}
  rs11066028   A              0.977            0.741-1.287      0.867                                         0.953   0.710-1.281   0.752                                         1.486   0.397-5.568   0.556

ORs, odds ratios; CI: confidence interval.

*p* value ≤ 0.05; Bonferroni\'s multiple adjustment was applied, with *p*\<0.00125.

We further characterized the SNPs in *ALDH2* SNPs using linkage disequilibrium (LD) and haplotype analyses. In the control group, one LD block was detected (Figure [1](#F1){ref-type="fig"}). This block consisted of 5 closely linked SNPs, rs886205, rs441, rs4646778, rs671 and rs11066028. Finally, a haplotype-based association study was performed to show the associations between *ALDH2* haplotypes and drug addiction risk (Table [5](#T5){ref-type="table"}). The haplotype "GTCAC" was associated with increased drug addiction risk (OR = 1.668; 95% CI, 1.328--2.094, *p* \< 0.001); in contrast, haplotype "ATCGC" was associated with decreased drug addiction risk (OR = 0.444; 95% CI, 0.281--0.704, *p* \< 0.001). Both of the haplotypes remained significant after Bonferroni correction (*p*\<0.00125).

![Haplotype block map for all the SNPs of the ALDH2 gene](oncotarget-08-8597-g001){#F1}

###### *ALDH2* haplotype frequencies and the association with drug addiction risk

  Block ID   Haplotype   Freq(case)   Freq(control)   χ2      Pearson\'s *p*                                OR      95% CI   *p*-adj   
  ---------- ----------- ------------ --------------- ------- --------------------------------------------- ------- -------- --------- ---------------------------------------------
  1          ATCGA       0.095        0.091           0.128   0.7201                                        0.999   0.756    1.320     0.996
             GTCAC       0.190        0.129           19.65   \< 0.001[\*](#tfn_009){ref-type="table-fn"}   1.668   1.328    2.094     \< 0.001[\*](#tfn_009){ref-type="table-fn"}
             GCAGC       0.278        0.283           0.101   0.7511                                        1.003   0.836    1.202     0.977
             ATCGC       0.024        0.049           12.76   \< 0.001[\*](#tfn_009){ref-type="table-fn"}   0.444   0.281    0.704     \< 0.001[\*](#tfn_009){ref-type="table-fn"}
             GTCGC       0.414        0.445           2.726   0.0987                                        0.859   0.731    1.009     0.065

OR: odd ratio; CI: confidence interval.

*p*-adj: *p*-value was adjusted by sex and age;

*p* value ≤ 0.05; Bonferroni\'s multiple adjustment was applied, with *p*\<0.00125.

DISCUSSION {#s3}
==========

In this study, we investigated the associations between eight selected *ALDH2* SNPs and risk of drug addiction in the Chinese Han population. We found that rs671 is significantly associated with an increased risk of drug addiction, while rs886205, rs441 and rs4646778 displayed decreased drug addiction risk. Our results suggest that the polymorphisms of *ALDH2* may play an important role in the risk of drug addiction in the Chinese Han population.

The *ALDH2* gene is located on chromosome 12. Rs671 (Glu504Lys) is a functional SNP in *ALDH2*, which could decrease the normal dehydrogenase activity of ALDH2 by approximately 90% \[[@R9], [@R10]\]. Previous study has shown that rs671 is associated with the risk of upper aerodigestive tract cancers in a Japanese population \[[@R11]\]. Later, Chinese study shown that individuals with the rs671 A allele may experience increased coronary heart disease risk because of interfering HDL-C and endothelial ADMA concentrations \[[@R12]\]. Recently, another study demonstrated that rs671 polymorphism may influence post-stroke epilepsy susceptibility by affecting plasma 4-HNE levels \[[@R13]\]. In our study, we found that "AG" and "AA" genotypes of rs671 are significantly associated with an increased risk of drug addiction. As a result, we concluded that carriers of the allele "A" of *ALDH2* rs671 may have low activity of ALDH2 enzymes and reduced metabolism, resulting in increased plasma concentration and delayed clearance of drugs. As far as we know, our study is the first to demonstrate that rs671 affect the development of drug addiction. Therefore, further research with a larger sample size is needed to confirm our data.

Rs886205 (A\>G) is an SNP in the promoter of *ALDH2*, which has been identified as a risk marker for esophageal squamous cell carcinoma in several Western populations \[[@R8]\]. Furthermore, one recent study has reported that rs886205 is associated with altered methylation levels of the negative regulatory promoter fragment and corresponding ALDH2 protein levels in alcohol-dependent patients' blood during withdrawal \[[@R14]\]. Our data shown that rs886205 is associated with a decreased risk of drug addiction. We concluded that it may be associated with drug addiction by influencing the adaptation of ALDH2 protein levels during detoxification.

Previous study have reported that rs4646778 polymorphism may influence the methadone dose and adverse reactions in patients with heroin addiction \[[@R15]\]. In our study, we also found that rs4646778 and rs441 displayed a decreased risk of drug addiction. However, literatures about rs4646778 and rs441 are relatively rare. So these results should be confirmed in further studies.

The Bonferroni correction is one of the most important methods used to address false discovery rates resulting from multiple testing. We found that only rs671 remained significant after Bonferroni correction, this may due to our strict SNP filtering criteria and small sample size. Additionally, the Bonferroni correction adjusts the value of alpha based on the number of tests performed, and is thus conservative; in some cases, truly significant differences may be deemed non-significant as a result of type II errors \[[@R16]\].

Our study had several intrinsic limitations. For example, drug addiction is a very complicated process, and environment factors such as level of education and income are important risk factors for drug addiction. Because our study had a relatively small size, and it did not incorporate data regarding education and income, we could not explore the interactions between genetic polymorphisms and environmental factors in drug addicts. Therefore, the relationship between *ALDH2* polymorphisms and environment factors in drug addicts must be evaluated in future studies.

Our present study provided evidence that SNPs in the *ALDH2* are associated with drug addiction in a Chinese Han population. It is possible that these variants are drug addiction risk factors and these data can provide a theoretical foundation for other researchers to further study the association between the *ALDH2* gene and drug addiction risk in the Chinese Han or other populations.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

In this study, all subjects were restricted to genetically unrelated Han Chinese individuals. A total of 692 unrelated former severe common illicit drug addicts (including opioid, stimulants, and marijuana) were recruited from the First People\'s Hospital of Yunnan Province from June 2014 to July 2016, and 700 healthy controls were randomly selected from the same hospital. Subjects were at least 18 years old who had one or more years of daily multiple uses of narcotics and underwent repeated random and observed urine tests. All patients had a clinical diagnosis of drug addiction. All psychiatric axis-I disorders were used as exclusion criteria. In addition, participants were excluded if they had a history of a seizure disorder (except cocaine-induced seizures) or severe medical illness. Individuals currently being treated with psychotropic medications or with psychiatric symptoms, including psychosis, dementia, suicidal or homicidal ideation, mania or depression requiring antidepressant therapy were also excluded.

All of the participants signed an informed consent agreement. The Human Research Committee for Approval of Research Involving Human Subjects, the First People\'s Hospital of Yunnan Province, approved the use of human blood in this study.

SNP selection and genotyping {#s4_2}
----------------------------

Eight SNPs were chosen from previously published polymorphisms associated with alcohol dependence \[[@R17]--[@R20]\], with minor allele frequencies \>5% in the HapMap Chinese Han Beijing population. DNA was extracted from whole-blood samples by GoldMag-Mini Whole Blood Genomic DNA Purification Kit (GoldMag Co. Ltd. Xi'an City, China). Quantification of the extracted DNA was performed using NanoDrop 2000 (Thermo Scientific, Waltham, Massachusetts, USA). The multiplexed SNP MassEXTENDED assay was designed using Sequenom MassARRAY Assay Design 3.0 Software \[[@R21]\]. Genotyping was done with the Sequenom MassARRAY RS1000 system using the standard protocol recommended by the manufacturer. Primers of PCR which were used for each SNP in our study are listed in Table [6](#T6){ref-type="table"}. Data management and analysis was done using Sequenom Typer 4.0 Software \[[@R21], [@R22]\].

###### Primers used for this study

  SNP_ID       1st_PCRP                          2st_PCRP                          UEP_SEQ
  ------------ --------------------------------- --------------------------------- --------------------------
  rs886205     ACGTTGGATGTCTCG CTTTTGGGTTTACGG   ACGTTGGATGCCTTT GACCCCAATGTGAAC   TGGAGCATCAGCCGGG
  rs2238152    ACGTTGGATGTGTTGTA AAAAGCACCAACC   ACGTTGGATGAATC CCACCTTTATTTAAG    CCAACCTCAAAGCCAAA
  rs4648328    ACGTTGGATGTTTAG CTTCTGCTCTCTACC   ACGTTGGATGTTTGC TCTGTAAGCTCCACG   TCTCTACCATATCCAGGT
  rs441        ACGTTGGATGAGCCTG GGTGCCAGAGAGA    ACGTTGGATGCCCTG ACAGCATTCACTTAG   GTGCCAGAGAGAGACTCGG
  rs4646778    ACGTTGGATGTATGCA GGCAACAAGACAAC   ACGTTGGATGGTTTT CTGCTATTGGCCCTG   ACAAGACAACTGGGAAAT
  rs671        ACGTTGGATGAGGTC CCACACTCACAGTTT   ACGTTGGATGTTGGT GGCTACAAGATGTCG   ggccgACACTCACAGTTTTCACTT
  rs11066028   ACGTTGGATGCCCC ACCATAAAGCTATGAC   ACGTTGGATGTGGAT GAAGTGTACCCACTG   gagaACAGCCAGTCTTGTTT
  rs7296651    ACGTTGGATGGGGCA AGACCCAGATTTGAA   ACGTTGGATGCACGT GGCCTGTAACTATGA   ACATCATTGGCCTATAACT

Statistical analysis {#s4_3}
--------------------

We used Microsoft Excel and the SPSS 18.0 statistical package (SPSS, Chicago, IL, USA) to perform statistical analyses. All *p* values presented in this study are two sided, and *p* = 0.05 was considered the cutoff for statistical significance. The differences in the characteristics of the case and control study population were compared using the chi-squared test (for categorical variables) and Welch\'s t tests (for continuous variables). In all analyses, the lower frequency allele was considered as the 'risk' allele. Control genotype frequencies for each SNP were tested for departure from Hardy-Weinberg equilibrium (HWE) using Fisher\'s exact test. The χ2 test was used to compare allele and genotype frequencies in cases and controls \[[@R23]\]. In order to assess the association between each genotype and the risk of drug addiction, three models were used, including additive model, dominant model and recessive model. The effects of the polymorphisms on the risk of drug addiction were expressed as odds ratios (ORs) with 95% confidence intervals (95% CIs), computed using unconditional logistic regression analysis with adjustments for age and sex \[[@R24]\]. Finally, the patterns of linkage disequilibrium (LD) and haplotype construction was evaluated by Haploview software package (version 4.2) \[[@R25]\]. All *p* values were Bonferroni corrected, and statistical significance was set at *p*\<0.00125 (0.05/40).

This work is supported by the Foundation of Educational Commission of Yunnan Province (2014Z038).

**CONFLICTS OF INTEREST**

The authors have no conflicts of interest to report.

[^1]: Co-first authors
